GLP-1 Warning Letters: The Marketing Claims That Got Telehealth Brands in Trouble

GLP-1 marketing compliance requires telehealth companies to ensure that advertising claims are truthful, adequately supported, and consistent with applicable FDA and FTC requirements. Claims involving weight-loss outcomes, medication approval, compounded products, and treatment availability can create regulatory risks when they mislead consumers or misrepresent the services being offered.

GLP-1 warning letters highlight the importance of reviewing promotional claims across paid advertisements, landing pages, testimonials, affiliate campaigns, influencer posts, and product descriptions. A disclaimer does not necessarily correct a misleading headline or an unsupported claim.

For telehealth brands, effective telehealth advertising compliance requires a process for reviewing claims before publication and monitoring them after campaigns launch. This article explains common marketing risks, provides examples of risky versus safer wording, and outlines a practical compliance checklist for healthcare businesses, marketers, affiliates, and influencers.

What Marketing Practices Can Trigger GLP-1 Compliance Issues?

GLP-1 warning letters and other enforcement actions must be evaluated according to the issuing authority, product, claims, and circumstances. However, several recurring advertising practices warrant particular attention.

1. Unsupported Weight-Loss Claims

Statements promising a specific amount of weight loss, guaranteed results, or rapid outcomes can mislead consumers when the advertiser cannot substantiate the claim or when the wording exaggerates what a treatment can achieve.

Examples of potentially problematic claims include:

• “Lose 30 pounds in 30 days.”
• “Guaranteed weight loss with every prescription.”
• “Everyone gets results.”
• “Lose weight without changing anything else.”

The risk is not limited to explicit guarantees. Testimonials, images, headlines, and the overall presentation can also imply that consumers should expect a particular outcome.

Safer wording: “Weight-management outcomes vary. A qualified healthcare professional can assess whether treatment may be appropriate based on your individual health needs.”

Numerical outcome claims should be supported by appropriate evidence and presented in a way that does not misrepresent the results consumers can reasonably expect.

2. Misrepresenting Compounded GLP-1 Medications

Compounded GLP-1 marketing requires particular care because compounded drugs are not FDA-approved, and the FDA does not review them for safety, effectiveness, and quality before marketing in the same manner as approved drugs.

Marketing can be misleading when it describes a compounded product as FDA-approved, implies that it is an FDA-approved branded medication, or presents compounding as a routine substitute without explaining the relevant distinctions.

Examples of claims to avoid include:

• “FDA-approved compounded semaglutide.”
• “The generic version of Wegovy.”
• “Identical to the FDA-approved brand.”
• “Compounded GLP-1s are available to everyone.”

Compounded products should not be presented as FDA-approved generic equivalents of branded medications. Compounding is subject to specific legal conditions, and its availability and permissibility cannot be assumed simply because a product contains the same active ingredient as an approved medication.

Safer approach: Identify the product accurately, distinguish compounded medication from FDA-approved products, and have qualified compliance and clinical professionals review statements about eligibility, availability, and appropriate use. Do not imply that compounding is automatically permissible or clinically appropriate for every patient.

3. Misleading Claims About FDA Approval

A telehealth company may provide access to a consultation without having FDA approval for every medication mentioned in its advertising. The presence of a licensed clinician does not make the medication itself FDA-approved.

Potentially misleading claims include:

• “Our entire GLP-1 program is FDA-approved.”
• “FDA-certified weight-loss treatment,” when that description is inaccurate.
• “Every patient qualifies for treatment.”
• Using imagery or language that falsely suggests FDA endorsement of a platform or brand.

Safer approach: Identify the specific FDA-approved medication accurately, when applicable. Distinguish approval of a drug for particular indications from the services offered by the telehealth company. Avoid suggesting that the FDA endorses a brand, platform, or individual provider unless the statement is specifically authorized and accurate.

4. Unsupported Safety Claims

GLP-1 medications can have side effects and may not be appropriate for every patient. Advertising that describes a medication as risk-free, suitable for everyone, or free from meaningful side effects can create a misleading impression.

Claims such as “100% safe,” “no side effects,” and “the perfect treatment for everyone” should not be used without regard to the available evidence and applicable requirements.

Safer approach: Describe the service accurately and direct patients to the applicable prescribing information and a qualified healthcare professional. Safety statements must be consistent with the medication’s current labeling and the evidence supporting the claim.

5. Misleading Testimonials and Influencer Endorsements

Testimonials do not remove an advertiser’s responsibility for the claims they communicate. A creator who describes dramatic weight-loss results may imply that other consumers can expect similar outcomes.

Under FTC endorsement principles, endorsements must be honest and not misleading. Material connections—including compensation, free services, or other incentives—must be disclosed clearly and conspicuously when required.

A disclosure does not make an otherwise misleading health claim acceptable.

Safer approach: Use genuine, authorized testimonials with appropriate context and disclosures. Do not present exceptional results as typical, script unsupported medical claims, or encourage creators to make statements they cannot substantiate.

Risky vs. Safer GLP-1 Advertising Copy

The following examples are intended for marketers reviewing headlines, paid advertisements, landing pages, affiliate promotions, and product descriptions. The alternative wording is a starting point for review, not automatic legal approval.

Risky wording	Safer direction
“Guaranteed to lose 20 pounds.”	“Weight-management outcomes vary. A clinician can assess whether treatment may be appropriate for you.”
“Get GLP-1s instantly, no questions asked.”	“Complete a clinical evaluation to determine whether you may qualify for treatment.”
“FDA-approved compounded semaglutide.”	Identify the compounded product accurately without implying that the compounded drug itself is FDA-approved.
“The generic version of Wegovy.”	Distinguish the compounded product from the FDA-approved branded medication.
“No side effects. No risks.”	Explain that treatment has potential risks and side effects, and direct patients to relevant medication information.
“Everyone qualifies.”	“Eligibility depends on an individual clinical evaluation.”
“The same results as branded medication for less.”	Avoid unsupported equivalence claims; accurately describe the product and service being offered.
“Our platform is FDA-approved.”	Describe the platform’s actual role and identify any FDA-approved medication separately.
“This treatment melts fat without effort.”	Describe the treatment and service factually without unsupported mechanisms or guaranteed outcomes.
“Prescription guaranteed.”	“Consultation and prescribing decisions depend on clinical assessment.”

The central principle of telehealth marketing rules is that the overall message must be accurate. A qualifying statement in small print may not correct a misleading headline, image, testimonial, or prominent claim.

How to Review GLP-1 Ads, Landing Pages, and Calls to Action

A compliant review should cover the complete consumer journey, not just the paid advertisement.

Paid Advertisement Headlines

Headlines should describe the service without promising an outcome, implying universal eligibility, or misrepresenting medication approval.

Risky: “The fastest way to lose weight with GLP-1s.”

Safer direction: “Explore clinician-led medical weight-management care.”

The alternative still requires review in context, including the services actually offered and any platform-specific restrictions.

Landing Pages and Product Descriptions

Landing pages should accurately identify the provider, consultation process, medication pathway, eligibility requirements, and relevant risks. Claims made in the advertisement should remain consistent with the destination page.

Avoid language suggesting that a prescription is automatic or that a patient can obtain medication regardless of medical history. Do not use branded medication names in a way that falsely implies the product being supplied is that brand.

Calls to Action

Calls to action can create compliance risks when they imply guaranteed access, bypass clinical evaluation, or use urgency to pressure consumers into a medical decision.

Instead of “Get your prescription guaranteed,” use a factual CTA such as “Request a consultation” or “Check consultation availability,” provided it accurately reflects the actual process.

SEO Content and Educational Pages

Organic blog content, comparison pages, and FAQs also require review. Publishing a claim in a blog rather than a paid advertisement does not automatically make it acceptable.

Content should distinguish FDA-approved products from compounded medications, explain relevant limitations, and avoid unsupported claims about outcomes or equivalence. Search keywords should not be inserted in ways that create a false impression about a product’s approval status or availability.

GLP-1 Affiliate Compliance: Requirements for Influencers and Publishers

GLP-1 affiliate compliance is important because telehealth companies may rely on third parties to promote consultations, virtual-care services, or weight-management programs. Affiliates can create compliance risks through their own websites, email campaigns, social posts, videos, testimonials, and paid traffic.

A contract alone is not a substitute for oversight. Brands should provide approved claims, prohibit unsupported medical statements, require appropriate disclosures, and monitor content published by their partners.

Affiliates and influencers should follow these practices:

• Use approved copy. Do not invent weight-loss statistics, clinical claims, pricing promises, or prescription guarantees.
• Disclose material relationships. Make compensation and other relevant connections clear and conspicuous where required.
• Avoid fabricated personal experiences. Testimonials must reflect genuine experiences.
• Represent products accurately. Do not describe compounded products as FDA-approved or as generic versions of branded medications.
• Review destination pages. An accurate social post can still direct consumers to a misleading landing page.
• Follow applicable platform policies. Affiliate approval from a brand does not automatically authorize an advertisement on Google or Meta.
• Report questionable claims. Affiliates should have a clear way to request clarification or escalate concerns before publishing.

Brands should establish affiliate agreements that define approval workflows, recordkeeping expectations, prohibited claims, disclosure requirements, monitoring rights, and procedures for promptly correcting or removing noncompliant content.

FDA, FTC, Google Ads, Meta, and LegitScript: Which Rules Apply?

There is no single approval that makes every GLP-1 campaign compliant. Different regulators and platforms evaluate different aspects of advertising and business operations.

Authority or policy	What marketers should review
FDA	Drug approval status, product labeling, prescription-drug promotion, and representations about compounded medications.
FTC	Truthful advertising, substantiation for health claims, deceptive practices, testimonials, endorsements, and material-connection disclosures.
Google Ads	Current healthcare and medicines policies, restricted drug-related content, certification requirements where applicable, and geographic restrictions.
Meta advertising policies	Current restrictions relevant to health and wellness, prescription drugs, personal attributes, and other applicable advertising categories.
LegitScript	Applicable healthcare merchant certification and advertising eligibility requirements, including requirements that may affect telehealth businesses and advertising partners.

Policies can change, and requirements vary by business model, product, market, and campaign. Meeting one platform’s requirements does not guarantee acceptance by another platform or establish compliance with applicable law.

For GLP-1 advertising rules, the practical implication is that legal review, platform-policy review, and operational certification checks should be treated as separate steps.

Marketing FDA-Approved Oral GLP-1 Medications

FDA approval does not authorize every advertising claim or remove the need to follow applicable prescription-drug promotion rules. Marketing must reflect the specific medication and its approved labeling.

When marketing an FDA-approved oral GLP-1 medication, brands should:

• Use the correct product name and describe its approved indication accurately.
• Follow applicable requirements for presenting benefits and risks.
• Avoid unsupported comparisons with injectable medications or other treatments.
• Avoid implying that every consumer is eligible or will experience a particular result.
• Confirm that the advertised service can lawfully provide the consultation and prescribing process being described.
• Verify the current prescribing information and advertising requirements before publishing or updating campaign content.

Branded oral medications and compounded products should not be treated as interchangeable in advertising. The product’s identity, approval status, indication, and applicable prescribing information determine how it should be described.

For businesses evaluating the commercial and operational considerations, oral GLP-1 telehealth programs and their clinical requirements are relevant to product descriptions, clinical evaluation, and patient communication.

A GLP-1 Marketing Compliance Checklist

Use this checklist before launching or updating an advertisement, landing page, email campaign, influencer post, or affiliate promotion.

• Product accuracy: Is the medication identified correctly, with its FDA approval status represented accurately?
• Claims substantiation: Can every express and implied health or weight-loss claim be supported by appropriate evidence?
• Balanced presentation: Are relevant risks and limitations presented appropriately for the advertising format?
• No guarantees: Have guaranteed outcomes, universal eligibility claims, and unsupported speed-of-results promises been removed?
• Compounding accuracy: Are compounded products clearly distinguished from FDA-approved drugs?
• Clinical integrity: Does the copy accurately explain that prescribing depends on an appropriate clinical evaluation?
• Affiliate disclosures: Are material connections disclosed clearly and conspicuously where required?
• Destination-page review: Does the landing page match the advertisement and avoid contradictory or misleading claims?
• Platform review: Have current Google Ads, Meta, and applicable LegitScript requirements been checked?
• Recordkeeping: Are the final creative, supporting evidence, approvals, disclosures, and relevant policy checks documented?
• Ongoing monitoring: Is there a process to review policy changes, new claims, affiliate content, and updated product labeling?

Keep a dated copy of approved creative and its substantiation. A checklist helps standardize reviews, but it does not replace qualified legal or regulatory advice.

What Should a Telehealth Brand Do After Receiving a Warning Letter?

A warning letter requires prompt, organized attention. The appropriate response depends on the issuing authority, the allegations, the deadlines, and the specific facts. The following is a general operational process, not a substitute for legal counsel.

Immediately: Preserve the Evidence

Save the letter, affected advertisements, landing pages, emails, affiliate posts, contracts, and relevant approval records. Document the date received and any response deadline.

As Soon as Possible: Escalate and Assess

Involve qualified legal and compliance counsel. Identify each cited claim, product, channel, and requested corrective action. Avoid assumptions about the letter’s scope.

Promptly: Address the Identified Risk

With counsel’s guidance, pause or remove affected claims and associated campaigns as appropriate. Notify relevant affiliates or vendors and prevent the same material from continuing to circulate.

Before Responding: Conduct a Broader Review

Examine related pages, advertisements, testimonials, email templates, and third-party promotions. Determine whether the issue is isolated or reflects a wider approval or monitoring failure.

By the Applicable Deadline: Respond Appropriately

Work with counsel to prepare a factual, complete response that addresses the agency’s requests. Do not ignore deadlines, speculate about facts, or make unsupported assurances.

After the Response: Document Corrective Action

Update approved claim libraries, contracts, review procedures, training, and monitoring systems. Assign responsibility for follow-up and retain records of changes.

Not every compliance issue leads to the same outcome. The response timeline should be adapted to the actual letter and applicable requirements.

How a White Label Telehealth Platform Can Support Compliance

A white label telehealth platform can provide technology and operational infrastructure for healthcare brands, but the platform itself does not guarantee compliant marketing, prescribing, or medication fulfillment.

Before selecting a partner, brands should clarify who is responsible for clinical services, prescribing decisions, medication fulfillment, advertising review, patient communications, and regulatory oversight. Responsibilities should be documented rather than assumed.

Useful partner capabilities may include controlled access to approved content, documented clinical workflows, clear escalation procedures, and support for maintaining appropriate records. Brands should also confirm which services the partner actually provides and which remain the brand’s responsibility.

Elite Care Health provides white-label telehealth infrastructure for healthcare brands and providers. Businesses should assess provider responsibilities, technology capabilities, and compliance workflows against their own operating model before launch.

Provider availability, state licensing, and clinical workflows are also important considerations when selecting a telehealth partner. These requirements should be assessed against the intended service areas and care model, including the key considerations for a 50-state telehealth provider network.

The objective is to establish a clearly governed process—from the first advertisement through clinical evaluation and ongoing patient support—with defined responsibilities and documented review procedures.

Frequently Asked Questions

1. What types of GLP-1 marketing claims can create regulatory risk?

Unsupported weight-loss promises, misleading FDA approval claims, inaccurate statements about compounded medications, unsubstantiated safety claims, and deceptive testimonials can create regulatory risk. The specific facts and applicable requirements determine whether a claim violates a rule.

2. Can telehealth companies advertise compounded GLP-1 medications?

Advertising must accurately represent the product and comply with applicable requirements. Compounded drugs are not FDA-approved, and compounding is subject to specific legal conditions. Brands should not imply that a compounded product is FDA-approved or automatically interchangeable with a branded medication.

3. Are affiliates responsible for GLP-1 advertising claims?

Affiliates and influencers should ensure their endorsements are truthful, avoid unsupported medical claims, and disclose material relationships where required. A brand’s approval does not automatically make misleading affiliate content acceptable.

4. Does LegitScript certification guarantee GLP-1 advertising approval?

No. LegitScript requirements, applicable laws, and advertising-platform policies are distinct. Certification does not guarantee approval by Google, Meta, or another platform, nor does it replace compliance with applicable law.

5. What should a telehealth brand do after receiving a GLP-1 warning letter?

Preserve relevant records, involve qualified counsel, assess the claims identified in the letter, address ongoing risks, and respond according to the applicable requirements and deadline. The response should be tailored to the actual allegations and requested corrective actions.

Build a More Defensible Telehealth Marketing Process

Effective telehealth advertising compliance requires more than editing individual headlines. Healthcare brands need a consistent process for substantiating claims, reviewing landing pages, monitoring affiliates, checking advertising-platform requirements, and documenting approvals.

Elite Care Health works with businesses building telehealth services and clinical infrastructure. Organizations evaluating the operational requirements for a new or expanding telehealth offering can contact Elite Care Health to discuss their business needs and available support.

This article provides general educational information and is not legal advice. Confirm current regulations, platform policies, medication labeling, and certification requirements with qualified professionals before launching a campaign.